Gay C, Benkelfat C, Renardet M
Encephale. 1986 Oct;12 Spec No:259-62.
Trazodone is a molecule which is already well known throughout the world for its antidepressant properties and its good global safety. We have conducted a large national study in outpatients. By means of a computerized communication network (233 psychiatrists equipped with Minitel), almost 2,000 depressed patients have been followed over a four week period of treatment with Pragmarel 100 mg, in less than three months. Computerized DSM III diagnostic criteria were used to define two sub-groups of patients. The results confirm the therapeutic indications of trazodone in various forms of depression, major affective disorders (689 cases) and other affective disorders (1,257 cases). 82% good and very good results were obtained in the overall population of patients, with a decrease by more than 50% in the initial score on the MADRS scale in 65% of cases. The low incidence of side effects and the excellent acceptability of treatment also confirm the date reported in the literature.
曲唑酮是一种因其抗抑郁特性和良好的整体安全性而在全球广为人知的分子。我们在门诊患者中进行了一项大型全国性研究。通过计算机化通信网络（233名配备了Minitel的精神科医生），在不到三个月的时间里，对近2000名抑郁症患者进行了为期四周的100毫克盐酸曲唑酮治疗随访。采用计算机化的DSM III诊断标准来定义两个患者亚组。结果证实了曲唑酮在各种形式的抑郁症、重度情感障碍（689例）和其他情感障碍（1257例）中的治疗指征。在总体患者人群中获得了82%的良好和非常好的结果，65%的病例中MADRS量表初始评分下降超过50%。副作用的低发生率和治疗的极佳可接受性也证实了文献中报道的数据。
